2026 Annual Meeting | C75 - Motor Neuron Disease
| 03:30 PM - 04:05 PM CDT | Speaker |
ALS Diagnosis and Treatment: Current Options and Promising Opportunities
Colin Quinn, MD |
| 04:05 PM - 04:40 PM CDT | Speaker |
What Causes ALS? Review and Update on ALS Pathophysiology
Defne Amado, MD, PhD |
| 04:40 PM - 05:15 PM CDT | Speaker |
Spinobulbar Muscular Atrophy: Review and Update
Christopher Grunseich, MD |
| 05:15 PM - 05:30 PM CDT | Speaker |
Questions and Answers
Colin Quinn, MD, Defne Amado, MD, PhD, Christopher Grunseich, MD |
| Colin Quinn, MD | Dr. Quinn has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abcuro. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Voyager Therapeutics. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catalyst Pharmaceuticals. |
| Defne Amado, MD, PhD | Dr. Amado has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Saltz Mongeluzzi & Bendesky P.C.. The institution of Dr. Amado has received research support from NIH/NINDS. Dr. Amado has received intellectual property interests from a discovery or technology relating to health care. |
| Christopher Grunseich, MD | The institution of Dr. Grunseich has received research support from AnnJi Pharmaceuticals. |